

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	O. F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,649 02/16/2006		02/16/2006	Giorgio Terenghi	TEPH109	4566
23579	7590	11/02/2006	EXAMINER		INER
	L. PABST		WANG, CHANG YU		
PABST PATENT GROUP LLP 400 COLONY SQUARE				ART UNIT	PAPER NUMBER
SUITE 1200				1649	
ATLANTA, GA 30361				DATE MAILED: 11/02/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

14

	Application No.	Applicant(s)				
Office Action Comments	10/568,649	TERENGHI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Chang-Yu Wang	1649				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be timil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on Sep 2	22, 2006.	•				
	action is non-final.					
,—	ince this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-14</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-14 are subject to restriction and/or e	election requirement.					
Application Papers		٠.				
9) The specification is objected to by the Examine	r					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119	·					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
·						
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08) Notice of Dransperson's Patent Drawing Review (PTO-946) Notice of Dransperson's Patent Drawing Review (PTO-946) Notice of Information Disclosure Statement(s) (PTO/SB/08)						
Paper No(s)/Mail Date	6) Other:					

Art Unit: 1649

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372. 1.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6, drawn to a nerve regeneration device.

Group II, claim(s) 7-10, drawn to a method for preparing a nerve regeneration device.

Group III, claim(s) 11-14, drawn to a method of nerve repair or regeneration.

- The inventions listed as Groups I-III do not relate to a single general inventive 2. concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- The 1st claimed invention is drawn to a nerve regeneration device comprising a 3. polyhydroxyalkanoate polymer in the form of a porous conduit wherein the polyhydroxyalkanoate polymer comprises 4-hydroxybutyrate. The polyhydroxyalkanoate polymer comprises 4-hydroxybutyrate is known in the art. Martin et al. teach polyhydroxyalkanoate polymer in a form of porous conduit comprising 4hydroxybutyrate (see p. 97, abstract; p.100; Biochem. Eng. J. 2003. 97-105), which meets the limitation of the 1st claim because the intended use in nerve regeneration is not given patentable weight. In addition, as also found in the International Search

Art Unit: 1649

Report, the Invention of the Group I was found to have no special technical feature that defined the contribution over the prior art of Truke. "Absorbable Biomaterial Is Suited for Diverse Applications" (INTERNET ARTICLE, ~Online! October 2001 (2001-10), XP002311372.). Therefore, claim 1 is anticipated by Martin et al. and Truke. Since the 1st claimed invention has no special technical feature, it cannot share a special technical feature with the other claimed inventions. Thus, Applicant's inventions do not contribute a special technical feature when view over the prior art, they do not have a single inventive concept and so lack unity of invention.

In addition, Group I is drawn to a technical feature of a nerve regeneration device. Group II is drawn to a technical feature of a method for preparing a nerve regeneration device. Group III is drawn to a technical feature of a method of nerve repair or regeneration. Since Groups I-III contribute different technical features, they do not have a single inventive concept and thus Applicant's inventions lack of unity of invention.

4. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Art Unit: 1649

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Page 4

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1649

6. Any inquiry of a general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Page 5

Papers relating to this application may be submitted to Technology Center 1600, Group 1649 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1600 is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chang-Yu Wang, Ph.D. whose telephone number is (571) 272-4521. The examiner can normally be reached on Monday-Thursday and every other Friday from 8:30 AM to 5:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, Ph.D., can be reached at (571) 272-0867.

Art Unit: 1649

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CYW October 25, 2006

UPERVISORY PATENT EXAMINED

Page 6